Danske Bank’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Danske Bank’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,389	Closed	-$1.18M	–	1605
2025 Q3	$1.18M	Sell	30,389 -12,565	-29%	-$408K	﹤0.01%	653
2025 Q2	$1.19M	Sell	42,954 -31,033	-42%	-$790K	﹤0.01%	699
2025 Q1	$1.64M	Buy	73,987 +31,157	+73%	+$641K	0.01%	728
2024 Q4	$847K	Buy	42,830 +14,240	+50%	+$325K	﹤0.01%	856
2024 Q3	$714K	Buy	28,590 +27,667	+2,998%	+$674K	﹤0.01%	866
2024 Q2	$0	Buy	+923	New	+$17.3K	﹤0.01%	1208

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Danske Bank's KNSA Position: Q4 2025 in Review

Danske Bank sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2025, closing a stake of 30,389 shares — an estimated $1.18M sold.

Danske Bank first reported a position in KNSA in Q2 2024 and held it in 6 quarters. The position peaked at $1.64M in Q1 2025. 224 funds tracked by Wall St. Rank hold KNSA as of Q4 2025.

Danske Bank reported no remaining Kiniksa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Danske Bank sold 30,389 Kiniksa Pharmaceuticals shares in Q4 2025, an estimated $1.18M.
Danske Bank first reported a position in Kiniksa Pharmaceuticals in Q2 2024 and held it in 6 quarters.
Danske Bank's Kiniksa Pharmaceuticals position peaked at $1.64M in Q1 2025.
224 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2025.

Based on Danske Bank's 13F filing for Q4 2025, filed 2 Feb 2026.